Luteolin exhibits anti-breast cancer property through up-regulating miR-203
Source abstract
Abstract
Luteolin is a representative of natural flavonoid that has anti-tumour properties. This study designed to check its impact on breast cancer and the underlying mechanisms. MDA-MB-453 and MCF-7 cells were administrated with luteolin and the following techniques were carried out: CCK-8 assay, FITC-PI double-staining and Western blot. qRT-PCR analysis was utilized to see the effects of luteolin on miR-203 expression. Besides, miR-203 expression was silenced by transfection with specific inhibitor. Luteolin remarkably declined MDA-MB-453 and MCF-7 cells viability and accelerated apoptosis which accompanied by Bax up-regulation, Bcl-2 down-regulation and Caspase-3 cleavage. Also, luteolin impeded TGFβ1-induced EMT, as evidenced by the decreased levels of Vimentin, Zeb1 and N-cadherin, as well as the increased level of E-cadherin. miR-203 was highly expressed in 22 pair of breast cancer tissues than the matched paracancerous tissues. Luteolin could elevate miR-203 level. Besides, luteolin's anti-tumour effects were partially eliminated by miR-203 silence. Further, luteolin inhibited Ras/Raf/MEK/ERK signalling, while the inhibitory effects were flattened by miR-203 silence. Luteolin significantly reduced breast cancer cells growth and EMT. Luteolin exerted its anti-tumour effects possibly involved the elevated expression of miR-203 and the inhibited Ras/Raf/MEK/ERK signalling.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Cancer Cells and Metastasis · Circular RNAs in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Galactophore, Linyi Central Hospital
References (40)
Show source-provided references
1. 10.3322/caac.2138710.3322/caac.21387 ↗
2. 10.7314/APJCP.2016.17.S3.4310.7314/APJCP.2016.17.S3.43 ↗
3. 10.5603/NMR.2017.000210.5603/NMR.2017.0002 ↗
4. Board PDQATE. Breast cancer treatment (PDQ(R)): patient version. PDQ cancer information summaries. Bethesda (MD): National Cancer Institute; 2002.
5. 10.1016/j.jep.2018.05.01910.1016/j.jep.2018.05.019 ↗
6. 10.1016/j.brainresbull.2015.09.00210.1016/j.brainresbull.2015.09.002 ↗
7. 10.1186/s12967-017-1151-610.1186/s12967-017-1151-6 ↗
8. 10.1016/j.jprot.2017.04.00510.1016/j.jprot.2017.04.005 ↗
9. 10.1039/C8FO02013B10.1039/C8FO02013B ↗
10. 10.1186/s13048-018-0468-y10.1186/s13048-018-0468-y ↗
11. 10.2147/BCTT.S14420210.2147/BCTT.S144202 ↗
12. 10.1002/jcp.2874210.1002/jcp.28742 ↗
13. 10.1371/journal.pone.021640010.1371/journal.pone.0216400 ↗
14. 10.1016/j.ejca.2016.11.00410.1016/j.ejca.2016.11.004 ↗
15. 10.1111/fcp.1248110.1111/fcp.12481 ↗
16. Li Y, Zhu H, Wang J, et al. miR-4513 promotes breast cancer progression through targeting TRIM3. Am J Trans Res. 2019;11:2431–2438.
17. 10.1002/jcsm.1240310.1002/jcsm.12403 ↗
18. 10.18632/oncotarget.2683810.18632/oncotarget.26838 ↗
19. 10.3727/096504018X1544438769653210.3727/096504018X15444387696532 ↗
20. Chen LZ, Ding Z, Zhang Y, et al. MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance. Eur Rev Med Pharmacol Sci. 2018;22:3734–3741.
21. 10.18632/oncotarget.1119310.18632/oncotarget.11193 ↗
22. 10.1186/1756-9966-31-5810.1186/1756-9966-31-58 ↗
23. Huang L, Jin K, Lan H. Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. Oncol Lett. 2019;17:3842–3850.
24. 10.1016/j.ctrv.2013.03.00910.1016/j.ctrv.2013.03.009 ↗
25. 10.1016/j.semcancer.2017.03.00610.1016/j.semcancer.2017.03.006 ↗
26. 10.1007/s40615-016-0324-y10.1007/s40615-016-0324-y ↗
27. 10.1016/j.clbc.2016.05.01210.1016/j.clbc.2016.05.012 ↗
28. 10.3390/nu907072810.3390/nu9070728 ↗
29. 10.1016/j.jsps.2016.04.01810.1016/j.jsps.2016.04.018 ↗
30. 10.1615/JEnvironPatholToxicolOncol.201401092310.1615/JEnvironPatholToxicolOncol.2014010923 ↗
31. 10.1016/j.cell.2009.11.00710.1016/j.cell.2009.11.007 ↗
32. 10.3892/or.2016.531110.3892/or.2016.5311 ↗
33. 10.1016/j.biopha.2019.10869810.1016/j.biopha.2019.108698 ↗
34. 10.3390/ijms1902044710.3390/ijms19020447 ↗
35. 10.2147/OTT.S10286210.2147/OTT.S102862 ↗
36. 10.1371/journal.pone.010012410.1371/journal.pone.0100124 ↗
37. 10.2147/OTT.S10871210.2147/OTT.S108712 ↗
38. 10.3892/etm.2017.482810.3892/etm.2017.4828 ↗
39. 10.1177/194760191142974310.1177/1947601911429743 ↗
40. 10.1016/j.bbamcr.2006.10.00110.1016/j.bbamcr.2006.10.001 ↗